Various studies showcased the effectiveness of HSP70-based vaccines in conjunction with tumour-associated antigens (TAAs), tumour-specific antigens (TSAs) and diverse vaccine types (DNA, protein and tumour cell lysate) across different cancers. This evidence concerns the gene HSPA1A and cancer.